Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sinopharm Group Co ( (HK:1099) ) has shared an announcement.
Sinopharm Group Co. Ltd. has announced a special resolution for a shareholders’ class meeting to grant the Board a mandate to repurchase up to 10% of its H Shares. This move is aimed at enhancing capital management flexibility and potentially stabilizing the company’s share price, reflecting a strategic decision to optimize shareholder value.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a leading pharmaceutical company in China, primarily engaged in the distribution of pharmaceutical and healthcare products. It operates in the healthcare industry with a focus on the Chinese market, providing a wide range of medical supplies and services.
Average Trading Volume: 7,707,441
Technical Sentiment Signal: Sell
Current Market Cap: HK$57.82B
For a thorough assessment of 1099 stock, go to TipRanks’ Stock Analysis page.